

Data Sheet

Product Name: Protease-Activated Receptor-2, amide

 Cat. No.:
 CS-7032

 CAS No.:
 190383-13-2


 Molecular Formula:
 C28H54N8O7

Molecular Weight: 614.78

Target: Protease-Activated Receptor (PAR)

Pathway: GPCR/G Protein

Solubility: H2O: 33.33 mg/mL (54.21 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Protease-Activated Receptor-2, amide (SLIGKV-NH₂) is a highly potent protease-activated receptor-2 (PAR2) activating peptide. Sequence: Ser-Leu-Ile-Gly-Lys-Val-NH2. IC50 & Target: PAR2^[1] **In Vitro:** The PAR2-activating peptides used are: SLIGKV-OH, SLIGRL-OH, SLIGKV-NH₂, SLIGRL-NH₂. The synthetic agonist peptides mimicking the tethered ligand of PAR2, Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH), Ser-Leu-Ile-Gly-Lys-Val-amide (SLIGKV-NH₂) Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL-OH) and their amidated forms Ser-Leu-Ile-Gly-Lys-Val-amide (SLIGKV-NH₂) Ser-Leu-Ile-Gly-Arg-Leu-amide (SLIGRL-NH₂) have also been demonstrated being able to activate the receptor without enzymatic cleavage, therefore, have been utilised as biological tools to examine physiological functions of PAR2. Protease-Activated Receptor-2, amide is one of a four family subgroup of G-protein-coupled receptors (GPCRs), called PARs. Protease-activated receptors are distinguished from other GPCRs through their unique proteolytic mechanism of activation. For PAR2, activating proteases, such as trypsin, tryptase and coagulation factors VIIa and Xa, cleave a specific extracellular amino-terminal domain of the receptor to reveal a "tethered ligand", SLIGKV- and SLIGRL- for human and mouse/rat PAR2, respectively, which subsequently interacts with the activation domain of the receptor, initiating intracellular signaling pathways^[1]. The protease-activated receptor-2 (PAR2) has been implicated in the pathogenesis of several inflammatory and autoimmune disorders, and is expressed in a wide variety of human tissues and cells. PAR2 belongs to a family of seven transmembrane domain receptor proteins that are activated by proteolysis. Enzymatic digestion exposes an N-terminus ligand sequence that binds intramolecularly to the activation site on the extracellular loop II, initiating a G-protein-mediated cell-signalling cascade and nuclear factor-kappa B (NF-κB)-regulated gene transcription^[2].

References:

[1]. Kanke T, et al. Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. Br J Pharmacol. 2005 May;145(2):255-63.

[2]. Ramelli G, et al. Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cellactivation in vivo. Immunology. 2010 Jan:129(1):20-7.

CAIndexNames:

L-Valinamide, L-seryl-L-leucyl-L-isoleucylglycyl-L-lysyl-

SMILES:

CC(C)[C@@H](C(N)=O)NC([C@H](CCCN)NC(CNC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@H](CO)N)=O)=O)=O)=O

Page 1 of 2 www.ChemScene.com

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com